Regulatory Nebilet PMS

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Hypertension; Heart Failure

Treatments: Drug: Nebivolol

Study type: Observational

Funder types: Industry

Identifiers

NCT01077661

113554

Details and patient eligibility

About

An open label, multi-centre, non-interventional post-marketing surveillance (PMS) to monitor the safety and effectiveness of Nebivolol administered in Korean patients according to the prescribing information

Full description

An open label, multi-centre, non-interventional post-marketing surveillance (PMS) to monitor the safety and effectiveness of Nebivolol administered in Korean patients according to the prescribing information

Nebivolol will be administered to Hypertension or Chronic heart failure (CHF) patients as described the prescribing information of Nebivolol by physician's decision.

Enrollment: 743 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

All subjects must satisfy the following criteria at PMS entry according to KFDA PMS regulation:

• Subjects with indication in the prescribing information
• Subjects administrated Nebivolol by physician's decision
• Subjects with no contraindication according to the prescribing information

Trial design

743 participants in 1 patient group

Patients administrated Nebivolol

Description:

There is only one group. This group includes patients administrated Nebivolol

Treatment:

Drug: Nebivolol